Revive Therapeutics (FRA:31R) Other Financing: €-0.03 Mil (TTM As of Mar. 2026)


What is Revive Therapeutics Other Financing?

Revive Therapeutics FRA:31R Other Financing is €-0.03 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Revive Therapeutics's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

Revive Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.03 Mil.

Revive Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Revive Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revive Therapeutics Other Financing Chart

Revive Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.66 0.00 0.20 0.00 0.00

Revive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 0.02 0.00 0.00 0.00

Revive Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.03 Mil mean?
Revive Therapeutics (FRA:31R) has a Other Financing of €-0.03 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Revive Therapeutics and its competitors.
Is Revive Therapeutics' Other Financing too high?
Revive Therapeutics' current Other Financing is €-0.03 Mil.
How does Revive Therapeutics' Other Financing compare to ZTS and UTHR?
Revive Therapeutics' Other Financing of €-0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Revive Therapeutics and its competitors. Revive Therapeutics's current Other Financing is €-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current Other Financing of €-0.03 Mil. The current Other Financing is €-0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current Other Financing is €-0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.